Edition:
United States

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

18.41USD
3:59pm EST
Change (% chg)

$-0.47 (-2.49%)
Prev Close
$18.88
Open
$19.32
Day's High
$19.41
Day's Low
$17.94
Volume
119,140
Avg. Vol
62,511
52-wk High
$24.85
52-wk Low
$11.74

Select another date:

Mon, Nov 13 2017

BRIEF-CRISPR Therapeutics appoints Michael Tomsicek as CFO

* CRISPR Therapeutics announces appointment of Michael Tomsicek as Chief Financial Officer

BRIEF-CRISPR and Casebia collaborate with CureVac on mRNA for gene-editing programs

* CRISPR Therapeutics and Casebia collaborate with CureVac on mRNA for gene-editing programs

BRIEF-Crispr Therapeutics files for mixed shelf offering of up to $300 mln - SEC filing‍​

* Crispr Therapeutics AG - files for mixed shelf offering of up to $300 million - SEC filing‍​ Source text: (http://bit.ly/2jeQFaT) Further company coverage:

BRIEF-CRISPR Therapeutics announces third quarter results

* CRISPR Therapeutics announces third quarter 2017 financial results and provides business update

BRIEF-Merck KGaA: Canadian patent office to grant patent application for CRISPR technology

* MERCK KGAA - CANADIAN PATENT OFFICE TO GRANT MERCK KGAA, DARMSTADT, GERMANY'S PATENT APPLICATION FOR CRISPR TECHNOLOGY

BRIEF-CRISPR Therapeutics promotes Samarth Kulkarni to CEO

* CRISPR Therapeutics announces promotion of Samarth Kulkarni, Ph.D. to chief executive officer

BRIEF-Crispr Therapeutics Ag qtrly ‍net loss per share attributable to common shareholders $0.56​

* Crispr Therapeutics announces second quarter 2017 financial results and provides business update

BRIEF-Crispr Therapeutics intellia therapeutics, Caribou Biosciences, ERS Genomics announce Appellate Brief seeking reversal of patent decision on Crispr/Cas9 gene editing

* Crispr Therapeutics, Intellia Therapeutics, Caribou Biosciences, ERS Genomics announce appellate brief seeking reversal of patent decision on crispr/cas9 gene editing

BRIEF-Crispr Therapeutics, Neon Therapeutics enter research collaboration​

* Crispr Therapeutics AG - ‍co, Neon Therapeutics enter research collaboration​

BRIEF-CRISPR Therapeutics announces patent for CRISPR/CAS genome editing in china

* CRISPR Therapeutics announces patent for CRISPR/CAS genome editing in China

Select another date: